Homan Abdollahzadeh, MD
Gastroenterology · Palm Springs, CANPI 1184634826
Payments from drug & device makers
Across 298 payments — averaging $1565.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$327K
- AbbVie$93K
- Sanofi US Services Inc.$32K
- Madrigal Pharmaceuticals$11K
- Redhill Biopharma Inc.$2K
- UCB Biosciences Inc.$2K
- plus $1K from 17 others
Across 4 payments — averaging $664.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dova Pharmaceuticals$3K
What the payments were for
- Consulting fees$1,66544%
- Food & beverage$2,10556%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 103 | $326,582 |
| AbbVie(2 entities) | 138 | $92,742 |
| Sanofi US Services Inc. | 8 | $31,675 |
| Madrigal Pharmaceuticals | 2 | $11,140 |
| Redhill Biopharma Inc. | 1 | $1,665 |
| UCB Biosciences Inc. | 2 | $1,600 |
| Dova Pharmaceuticals | 1 | $250 |
| Johnson & Johnson | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| Gilead | 5 | $99 |
| Pfizer | 6 | $95 |
| Merck | 5 | $87 |
| Bristol Myers Squibb | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Boston Scientific | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Organon | 1 | $25 |
| Micro-tech Endoscopy USA, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Amgen | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Ambu Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$466,488 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 14 | $318,966 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 1,125 | $197,069 |
| EntyvioVedolizumab | 20 | $184,608 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $60,175 |
| CreonLipase/Protease/Amylase | 30 | $54,712 |
| RezdiffraResmetirom | 12 | $46,372 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 653 | $35,233 |
| LinzessLinaclotide | 25 | $21,353 |
| Mesalamine | 56 | $16,556 |
| TaliciaOmeprazole/Amoxicill/Rifabutin | 18 | $13,801 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 529 | $9,278 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 364 | $7,866 |
| Ursodiol | 39 | $7,696 |
| Tenofovir Disoproxil Fumarate | 14 | $7,651 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 362 | $5,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $99 | $318,96614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $116 | $184,60820 claims |
| AbbVieCreon, Linzess | $92,742 | $76,06555 claims |
| UCB, Inc.Cimzia (2 Pack) | $17 | $60,17511 claims |
| Madrigal PharmaceuticalsRezdiffra | $11,140 | $46,37212 claims |
| Redhill Biopharma Inc.Talicia | $1,665 | $13,80118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Palm Springs
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.